MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Morales, María Luz, Arenas, Alicia, Ortiz-Ruiz, Alejandra, Leivas, Alejandra, Rapado, Inmaculada, Rodríguez-García, Alba, Castro, Nerea, Zagorac, Ivana, Quintela-Fandino, Miguel, Gómez-López, Gonzalo, Gallardo, Miguel, Ayala, Rosa, Linares, María, Martínez-López, Joaquín
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6901485/
https://ncbi.nlm.nih.gov/pubmed/31819100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-54901-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars